Company intelligence / Profile preview
BridgeBio Pharma
Palo Alto, California, United Statesbridgebio.com ↗
- Ownership
- Public · BBIO
- Development stage
- Commercial
01
Overview
BridgeBio has multiple programs in development, with acoramidis for ATTR cardiomyopathy as a key focus for launch in 2024. The company has positive Phase 1 data for BBP-711 for PH1, and infigratinib received Breakthrough Therapy Designation for achondroplasia. The company recently launched BridgeBio Oncology Therapeutics (BBOT) with $200M in external capital to advance its precision oncology pipeline.
- Therapeutic areas
- CardiovascularNephrologyEndocrinologyOncologyRare DiseasesNeurology
- Modalities
- Small moleculesGene therapyAAV gene therapy
- Industry
- Biotech
02
Drug pipeline
23 assets22 more assets in the full pipeline.
03
Financials
- Market cap
- $14.5B
- Total revenue
- $502.1M
- Enterprise value
- $15.4B
Beyond the preview
Go deeper on BridgeBio Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BridgeBio Pharma.